Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Markers for anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) therapy in melanoma.

Methods in molecular biology (Clifton, N.J.) - 1 Jan 2014

Postow Michael A, Yuan Jianda, Kitano Shigehisa, Lesokhin Alexander M, Wolchok Jedd D

Abstract excerpt

Therapeutic strategies that block Cytotoxic T lymphocyte antigen-4 (CTLA-4) enhance antitumor immunity and prolong the lives of patients with metastatic melanoma. However, only a subset of patients benefit, and responses are often delayed due to heterogeneous response kinetics. Ongoing monitoring of the immunologic effects of therapy and correlating these immunologic changes with patient outcomes continue to be...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antigens, Neoplasm
Share to Blood Specimen Collection

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Separation

Share to Cryopreservation

Share to CTLA-4 Antigen

Share to Immunity, Humoral

Share to Immunotherapy

Share to Ipilimumab

Source

Identifiers

PMID: 24258975
DOI: 10.1007/978-1-62703-727-3_6

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 9 closest

Markers for anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) therapy in melanoma.PMID 24258975Read ↗

Phenotypic characterization of tumor CTLA-4 expression in melanoma tissues and its possible role in clinical response to IpilimumabSemantic proximity Read ↗

Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade.Semantic proximity Read ↗

CTLA-4 blockade increases antigen-specific CD8+ T cells in prevaccinated patients with melanoma: three casesSemantic proximity Read ↗

Characterization of circulating T cells specific for tumor-associated antigens in melanoma patientsSemantic proximity Read ↗

Characterization and augmentation of CD4+ cytotoxic T cell lines against melanoma.Semantic proximity Read ↗

CTLA4 promoter methylation predicts response and progression-free survival in stage IV melanoma treated with anti-CTLA-4 immunotherapy (ipilimumab)Semantic proximity Read ↗

CTLA-4 blockade boosts the expansion of tumor-reactive CD8+ tumor-infiltrating lymphocytes in ovarian cancer.Semantic proximity Read ↗

Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial.Semantic proximity Read ↗

Evaluation of six CTLA-4 polymorphisms in high-risk melanoma patients receiving adjuvant interferon therapy in the He13A/98 multicenter trial.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.